| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 10,705 | 10,775 | ||
| Prepaid expenses and other current assets | 788 | 519 | ||
| Total current assets | 11,493 | 11,294 | ||
| Property and equipment, net | 12 | 7 | ||
| Total assets | 11,505 | 11,301 | ||
| Accounts payable | 516 | 235 | ||
| Total current liabilities | - | 1,206 | ||
| Accrued expenses | 1,150 | 971 | ||
| Total liabilities | 1,666 | 1,206 | ||
| Common stock, 0.0001 par value, 100,000,000 shares authorized 5,784,770 and 1,733,717 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 1 | - | ||
| Additional paid-in capital | 162,521 | 160,386 | ||
| Accumulated deficit | -152,683 | -150,291 | ||
| Total stockholders' equity | 9,839 | 10,095 | ||
| Total liabilities and stockholders' equity | 11,505 | 11,301 | ||
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. (PHIO)